These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26219569)

  • 21. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
    Karkoulis PK; Stravopodis DJ; Voutsinas GE
    Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
    Douglas M; Lim AR; Porter JR; West K; Pink MM; Ge J; Wylie AA; Tibbits TT; Biggs K; Curtis M; Palombella VJ; Adams J; Fritz CC; Normant E
    Mol Cancer Ther; 2009 Dec; 8(12):3369-78. PubMed ID: 19952119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
    Yi B; Yang J; Wang L
    Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells.
    Chen PH; Chang JT; Li LA; Tsai HT; Shen MY; Lin P
    Mol Pharmacol; 2013 Mar; 83(3):605-12. PubMed ID: 23229511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular determinants of the response of cancer cells towards geldanamycin and its derivatives.
    Seo EJ; Khelifi D; Fayez S; Feineis D; Bringmann G; Efferth T; Dawood M
    Chem Biol Interact; 2023 Sep; 383():110677. PubMed ID: 37586545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.
    Kim HR; Kim WS; Choi YJ; Choi CM; Rho JK; Lee JC
    Mol Oncol; 2013 Dec; 7(6):1093-102. PubMed ID: 23993685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway.
    Qu Z; Dong H; Xu X; Feng W; Yi X
    Diagn Pathol; 2013 May; 8():70. PubMed ID: 23635099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
    Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
    PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG.
    Hadley KE; Hendricks DT
    BMC Cancer; 2014 May; 14():334. PubMed ID: 24886060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of heat shock protein (Hsp) 90 potentiates the antiproliferative and pro-apoptotic effects of 2-(4'fluoro-phenylamino)-4H-1,3-thiazine[6,5-b]indole in A2780cis cells.
    Solárová Z; Kello M; Varinská L; Budovská M; Solár P
    Biomed Pharmacother; 2017 Jan; 85():463-471. PubMed ID: 27887849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
    Honkanen T; Wilenius E; Koivunen P; Koivunen JP
    Int J Oncol; 2017 Aug; 51(2):599-606. PubMed ID: 28656214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
    Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.